Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Not applicableStudy completedNCT01106781
What this trial is testing

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 591
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Not applicableUnknownNCT01838577
What this trial is testing

Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study

Who this might be right for
EGFR Mutation Positive Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 2,000
Early research (Phase 1)Study completedNCT01999985
What this trial is testing

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung CancerNon-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute 25
Testing effectiveness (Phase 2)Looking for participantsNCT05099172
What this trial is testing

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation
Bayer 400
Not applicableUnknownNCT01717105
What this trial is testing

Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

Who this might be right for
Metastatic Non-Small-Cell Lung Cancer
Grupo Gallego de Cancer de Pulmon 225
Testing effectiveness (Phase 2)UnknownNCT05394233
What this trial is testing

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung CancerEGFR Gene Mutation
Sichuan Cancer Hospital and Research Institute 20
Not applicableStudy completedNCT01185314
What this trial is testing

To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 1,270
Not applicableEnded earlyNCT02483416
What this trial is testing

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 30
Not applicableStudy completedNCT05517083
What this trial is testing

Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Pusan National University Hospital 41
Testing effectiveness (Phase 2)Study completedNCT06521034
What this trial is testing

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Sensitizing Mutation
Yongchang Zhang 124
Testing effectiveness (Phase 2)Study completedNCT02264210
What this trial is testing

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Who this might be right for
Lung NeoplasmsSquamous Cell Lung CancerAdenocarcinoma of the Lung+4 more
Sun Yat-sen University 128
Not applicableWithdrawnNCT06075615
What this trial is testing

Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer
Not applicableStudy completedNCT01255150
What this trial is testing

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07699952
What this trial is testing

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationHER2
Yongsheng Wang 35
Early research (Phase 1)Study completedNCT06348888
What this trial is testing

Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation+1 more
Bayer 30
Testing effectiveness (Phase 2)UnknownNCT03382795
What this trial is testing

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Korea University Guro Hospital 63
Large-scale testing (Phase 3)Active Not RecruitingNCT04988295
What this trial is testing

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 776
Large-scale testing (Phase 3)Study completedNCT01544179
What this trial is testing

IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 265
Next Page